Trigen InterTAN vs Sliding Hip Screw RCT
Launched by SMITH & NEPHEW ORTHOPAEDICS AG · Feb 24, 2017
Trial Information
Current as of May 11, 2025
Terminated
Keywords
ClinConnect Summary
A multicentre, randomised controlled trial, conducted in the UK will recruit 180 subjects, randomised to receive either the Trigen InterTAN Nail or the Sliding Hip Screw.
Subjects presenting at participating hospitals with AO/OTA 31-A1 or A2 fractures will be assessed against the eligibility criteria and approached for Informed Consent.
Subjects who are considered eligible and who have provided Informed Consent will be randomised using iDataFax to one of the two treatment options.
Subjects will be operated on according to standard procedure and the Instructions for Use.
A daily inpatien...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • has closed trochanteric hip fracture (AO/OTA 31-A1 or A2) requiring treatment with internal fixation
- • has injury due to low energy trauma
- • is independently ambulatory in living environment prior to injury (walking aids permitted)
- • is \>60 years of age
- • is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires
- • has consented to participate in the study by signing the Ethics Committee (EC) approved ICF
- • has definitive fracture fixation \<72h from admission
- Exclusion Criteria:
- • has any additional injury or disability affecting mobility or affecting use of walking aids
- • has a pathological fracture (excluding osteoporotic fracture)
- • has an existing implant in study hip
- • has diagnosis of an immunosuppressive disorder
- • has an active infection, treated or untreated, systemic or at the site of the - has a condition that may interfere with the outcome of the study, including but not limited to: Paget's disease, Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, renal insufficiency or neuromuscular disease
- • has a BMI \>40
- • has an inadequate bone stock to support the device which would make the procedure unjustifiable, including but not limited to: severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia
- • is pregnant or plans to become pregnant during the course of the study
- • is a prisoner or is facing impending incarceration
- • in the opinion of the PI, has an emotional or neurological condition that would interfere with their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse
- • is entered in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days
- • is known to be at risk for lost to follow-up, or failure to return for scheduled visits
About Smith & Nephew Orthopaedics Ag
Smith & Nephew Orthopaedics AG is a leading global medical technology company specializing in advanced orthopedic solutions. With a commitment to innovation and patient care, the organization develops and commercializes a comprehensive range of products, including joint reconstruction, trauma management, and advanced wound care solutions. Through rigorous clinical trials and research initiatives, Smith & Nephew aims to enhance surgical outcomes and improve the quality of life for patients worldwide. Their dedication to excellence is reflected in their collaborative approach with healthcare professionals and a strong emphasis on evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liverpool, , United Kingdom
Plymouth, , United Kingdom
Truro, , United Kingdom
Exeter, , United Kingdom
Gloucester, , United Kingdom
Patients applied
Trial Officials
Stephen Mitchell, MBChB FRCS
Principal Investigator
University Hospitals Bristol and Weston NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials